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Abstract
Background: β-Thalassemia is a prevalent genetic disease in Mediterranean countries. The most common 
treatments for this disease are blood transfusion plus iron chelation (BTIC) therapy and bone marrow 
transplantation (BMT). Patients using these procedures experience different health-related quality of life 
(HRQoL). The purpose of the present study was to measure HRQoL in these patients using 2 different 
multiattribute quality of life (QoL) scales. 
Methods: In this cross-sectional study, data were gathered using 3 instruments: a socio-demographic 
questionnaire, EQ-5D, and SF-36. A total of 196 patients with β-thalassemia were randomly selected from 
2 hospitals in Shiraz (Southern Iran). Data were analyzed using logistic regression and multiple regression 
models to identify factors that affect the patients’ HRQoL. 
Results: The average EQ-5D index and EQ visual analog scale (VAS) scores were 0.86 (95% CI: 0.83–0.89) 
and 71.85 (95% CI: 69.13–74.58), respectively. Patients with BMT reported significantly higher EQ VAS scores 
(83.27 vs 68.55, respectively). The results showed that patients who lived in rural area and patients with BMT 
reported higher EQ VAS scores (rural; β = 10.25, P = .006 and BMT; β = 11.88, P = .000). As well, SF-36 between 
2 groups of patients were statistically significant in physical component scale (PCS).
Conclusion: Patients in the BMT group experienced higher HRQoL in both physical and mental aspects 
compared to those in the BTIC group. More studies are needed to assess the relative cost-effectiveness of these 
methods in developing countries.
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Implications for policy makers
• Given the limited resources of  healthcare systems and existence of multiple approaches to the treatment for some diseases such as β-thalassemia, 
it is necessary to select a treatment procedure that has more utility and less cost. 
• Since we aimed to compare quality of life between the two treatments and not quality adjusted life years, we did not take into account those 
people who died during the follow up. 
• There is generally higher mortality associated with bone marrow transplantation (BMT) compared with transfusion and chelation which can 
decrease the total overall impact of BMT compared with transfusion and chelation.
• Costs of treatment were not calculated in this study and more studies are needed to decide about cost-effectiveness of these 2 therapies.
Implications for public
Knowing which treatments lead to the higher quality of life (QoL) is crucial for β-thalassemia patients. The present study gives details about 
QoL resulted from 2 therapeutic procedures. However, we should not choose a therapeutic method just based on higher QoL without considering 
mortality and cost-effectiveness and ease of access.
Key Messages 
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Introduction
β-Thalassemia is the most common monogenic disorder in 
Mediterranean countries, parts of North and West Africa, 
Southeast Asia, and the Indian subcontinent.1 Its typical 
symptom is reduction or fault in the construction of the 
hemoglobin chain which leads to failure in the hematopoietic 
process.2,3 This disease is specified by chronic and severe 
anemia manifestation, lack of proper growth, enlargement 
of the spleen, and liver and bone deformities, with especially 
visible changes in facial bones.4 It has been estimated that 
more than 25 000 β-thalassemia cases are living in Iran. The 
highest incidence is in the Caspian area in the north and in the 
Persian Gulf and Oman Sea area in the south. The incidence 
rate of this disease is 3-100/100 000 people.5 Treatment for 
β-thalassemia involves regular blood transfusion and disposal 
of excess iron from the body, especially liver. An alternative 
method is bone morrow transplantation (BMT) from healthy 
people.6 Long, regular and unpleasant therapeutic regimens 
influence all aspect of patients’ lives, including mental health, 
social life, and health-related quality of life (HRQoL).7-12 
Over the last 2 decades, there has been an increasing interest 
in assessment and improvement of HRQoL in patients with 
chronic diseases.13 In addition, due to limited resources in 
the healthcare systems, the demand for analyzing the cost-
effectiveness of treatments is increasing.14,15 One of the most 
important issues in economic evaluation is measuring and 
evaluating different aspects of a patient’s HRQoL.15 Since all 
studies on HRQoL in β-thalassemia patients of Iran have 
focused on those who use blood transfusion,3,8,16-20 we decided 
to compare HRQoL in patients that use blood transfusion 
plus iron chelation (BTIC) therapy and those who have had 
bone marrow transplantation (BMT) using 2 different multi-
attribute quality of life (QoL) scales. In addition, we tried to 
assess the effects of different socio-economic characteristics 
on HRQoL. 
Methods
Study Design and Subjects 
We conducted a cross-sectional study on β-thalassemia 
patients who used BTIC and BMT in Shiraz province 
(Southern Iran). Two hundred ten subjects were selected 
from 2 hospitals using simple random sampling. The sample 
included BTIC patients who constantly visited the hospitals 
and had a medical record, BMT patients whose medical record 
and addresses or phone numbers were available, and patient 
with no congenital disease (160 users of BTIC and 50 users of 
BMT). All patients were listed in a Microsoft Excel sheet and 
then, based on random figures table, 160 users of BTIC and 
50 patients who have undertaken BMT were selected. From 
the selected patients 6 in BMT and 8 in BTIC group were not 
able to attend in the study because of death of BMT patients, 
change in address, and unwillingness to participate in the 
study. All remaining subjects signed an informed consent 
form. All the selected patients were asked to fill out SF-36 
and EQ-5D questionnaires by a trained investigator. In the 
cases that patients do not have enough literacy to understand 
questionnaire’s items and for the children, the questionnaire 
completed through interview with patient. Before filling out 
the questionnaires or performing interviews, the patients 
received information about the purpose and applications 
of the research. QoL data for BMT patients were collected 
between 8 months and 18 years after BMT. For BTIC patients 
questionnaire were filled in the time they refer for blood 
transfusion. Patients with less than 50% of national average 
income were classified as low-income level, and patients 
with higher 50% of national average, were classified as high-
income group. The remaining were classified as middle-
income group. In the end, valid questionnaires were collected 
from 196 patients (152 BTIC and 44 BMT patients). 
Measures
Data were gathered using 3 instruments: a socio-demographic 
questionnaire, the validated Persian version of EQ-5D 3L, EQ 
visual analog scale (VAS), and SF-36.21 EQ-5D is one of the 
general tools for measuring QoL. It has 2 parts. The first part 
contains 5 questions about mobility (MO), self-care (SC), 
usual activities (UA), pain/discomfort (P/D) and anxiety/
depression (A/D). Each question has 3 possible answers, 
including no problem, some or moderate problem, and severe 
or extreme problem. In this study, due to the absence of a 
locally set of values, as suggested by EuroQoL Group, the EQ-
5D index score was calculated using the UK EQ VAS value 
set. The second part (EQ VAS) is a graded tool for health 
status where the respondents select a score from 0 to 100 to 
represent their level of health, with higher scores indicating 
better QoL.15,22,23 Short Form Health Survey (SF-36) is another 
instrument used for assessing general health of β-thalassemia 
patients. This is also a general tool for measuring QoL in 
different contexts.24 SF-36 assesses general health in eight 
dimensions: physical functioning (PF), role physical (RP), 
bodily pain (BP), general health (GH), role emotional (RE), 
social functioning (SF), vitality (VA), and mental health 
(MH). The mean of these dimensions is calculated from 0 to 
100, with 0 and 100 indicating the worst and the best health 
conditions, respectively.8
Data Analysis
Continuous variables were presented by mean and standard 
deviation (SD) and discrete variables were reported in 
absolute numbers and percentages. Responses to the EQ-5D 
dimensions were dichotomized to having problem or not 
and were analysed using logistic regression. Also the factors 
affecting QoL were identified using multiple regression 
models, where the EQ-5D index score was the dependent 
variable and the effect of each independent variable on QoL 
was calculated. SF-36 scores were also compared for BTIC 
and BMT patients, and multiple linear regression models 
were used for analyzing the effect of independent variables 
on 8 dimensions of SF-36. All analyses were done in STATA/
SE 12.0. 
Results
The patients’ characteristics are shown in Table 1. Patients’ age 
varied from 5 to 35 years and the average age of respondents 
was 20 years (SD = 7.49). 58.16% of the respondents were male. 
About 83% of the patients had less than 12th grade education, 
and 39%, 28%, and 33% of the participants were in the low-, 
middle-, and high-income groups, respectively. Moreover, 
comparison of demographic characteristics between the 2 
groups (BTIC and BMT) showed significant differences only 
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in the level of income and residence indicators (P < .05). 
EQ-5D Descriptive
Overall, 3.57%, 2.04%, 3.57%, 32.14%, and 28.57% of the 
β-thalassemia patients reported ‘‘some or extreme problems’’ 
in MO, S/C, UA, P/D, and A/D dimensions of the EQ-5D 
index, respectively (Table 2). Patients less than 18 years old 
were significantly different in S/C and A/D dimensions than 
other age groups. Patients who lived in urban areas had 
more problems in all the dimension of EQ-5D, except MO. 
Table 1. The Characteristics of the Patients
Variable 
Total BTIC BMT P
 No. % No. % No. %
Gender
Male 114 58.16 90 59.21 24 54.54
.581
Female 82 41.84 62 40.79 20 45.46
Age group
<18 73 37.24 55 36.18 18 40.90
.74818-25 67 34.18 54 35.52 13 29.54
≥25 56 28.58 43 28.30 13 29.56
Education (y)
≤12 163 83.16 127 83.55 36 81.81
.787
>12 33 16.84 25 16.45 8 18.19
Income
Low 77 39.28 71 46.71 6 13.63
<.001Middle 55 28.06 42 27.63 13 29.54
High 64 32.66 39 25.66 25 56.83
Living place
Urban 175 89.28 140 92.10 35 79.54
.018
Rural 21 10.72 12 7.90 9 20.46
Supplementary Insurance
Yes 47 23.98 37 24.34 10 22.72
.825
No 149 76.02 115 75.66 34 77.28
Abbreviations: BTIC, blood transfusion plus iron chelation; BMT, bone marrow transplantation. 
Table 2. Results of the EQ-5D Descriptive
Variables
Mobility Self-Care Usual Activities Pain/Discomfort Anxiety/Depression
% Reporting 
any Problems P
% Reporting 
any Problems P
% Reporting 
any Problems P
% Reporting 
any Problems P
% Reporting 
any Problems P
Gender
Male 5.26 .132 3.51 .087 5.26 .132 32.46 .912 28.95 .891
Female 1.22 0.00 1.22 31.71 28.05
Age group
<18 6.85 .093 5.48 .032 6.85 .093 26.03 .344 15.07 .005
18-25 0.00 0.00 0.00 34.33 38.81
≥25 3.57 0.00 3.57 37.50 33.93
Education (y)
≤12 4.29 2.45 4.29 33.74 26.38
>12 0.00 .225 0.00 .363 0.00 .225 24.24 .287 39.39 .131
Income
Low 3.90 .101 3.90 .280 3.90 .689 24.68 .172 33.77 .406
Middle 7.27 0.00 1.82 34.55 23.64
High 0.00 1.56 4.69 39.06 26.56
Living place
Urban 3.43 .756 2.29 .484 4.00 .351 33.14 .387 32.00 .002
Rural 4.76 0.00 0.00 23.81 0.00
Insurance
Yes 0.00 .130 2.13 .961 4.26 .772 34.04 .749 25.53 .597
No 4.70 2.01 3.36 31.54 29.53
Treatment
BTIC 3.95 .598 1.97 .902 3.59 .598 26.32 .001 34.87 <.001
BMT 2.27 2.27 2.27 52.27 6.82
Total 3.57 2.04 3.57 32.14 28.57
 Abbreviations: BTIC, blood transfusion plus iron chelation; BMT, bone marrow transplantation. 
Notes: P-value: chi-squared test; No sign: not significant.
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Furthermore, the frequency of ‘‘some or extreme problems’’ 
responses to MO, UA, and A/D dimensions was higher in the 
BTIC group, and respondents with BMT had more problems 
in SC and P/D. However, these differences were significant in 
P/D and A/D. EQ-5D Index and VAS Scores.
The average EQ-5D index and EQ VAS scores were 0.86 (95% 
CI: 0.83–0.89) and 71.85 (95% CI: 69.13–74.58), respectively 
(Table 3). There were significant differences between the EQ 
VAS scores of different income groups, with the high-income 
group having the highest scores. The results also showed that 
BMT patients had significantly higher EQ VAS score than 
BTIC patients (83.27 vs 68.55, respectively). Finally, there was 
significant differences in EQ VAS score between patients of 
different residence groups.
Regression Analysis
Multivariate logistic regression analysis was used for EQ-
5D index and EQ VAS scores (Table 4). As the data show, 
EQ VAS scores were significantly associated with residence 
and treatment approach; that is, patients living in rural area 
and patients receiving BMT reported higher EQ VAS scores 
(rural; β: 10.25, P = .006 and BMT; β: 11.88, P = .000). 
SF-36 Scores and Regression Analysis
In this study, SF-36 scores were also used to compare the 
health of patients who received each of the 2 treatment 
approaches (Table 5). The results show significant differences 
between the 2 groups in PF, RE, and RP dimensions of SF-36. 
As well, SF-36 between 2 groups of patients were statistically 
significant in physical component scale (PCS).
Multiple linear regression was applied to SF-36 scores (Table 
6). As Table 6 shows, patients receiving BMT had higher SF-
36 scores (PF; β: 9.11, RP; β: 16.85, BP; β: -2.14, GH; β: 4.27, 
MH; β: 4.41, RE; β: 22.45, SF; β: 7.22, VA; β: 4.44, PCS; β: 3.37, 
MCS; β: 4.11). The data also show that type of treatment was 
significantly associated with SF-36 scores.
Discussion
To our best knowledge, all studies on the QoL of patients with 
β-thalassemia in Iran were done with patients who received 
blood transfusion and iron chelation therapy.3,8,16-20 This study 
is the first to investigate and compare QoL in patients 
receiving blood transfusion and bone morrow transplantation. 
Iran is one of the pioneers in using BMT for β-thalassemia 
patients,25 and thus this study can be remarkable. EQ-5D and 
SF-36 were used to examine the patient’s HRQoL, then scores 
resulted from 2 questionnaires were compared. Also, the 
relation between dimensions of the questionnaires and 
patient’s characteristics were examined. SF-36 has been used 
in many countries to study HRQoL in patients with 
β-thalassemia.8,16,26,27 EQ-5D has also been used in several 
other studies.10,11,26 In the present study, EQ-5D was used for 2 
reasons; using this questionnaire allows for converting utility 
scores into quality-adjusted life-years (QALYs), and the 
questionnaire is simple and does not need much time to 
complete.15 Using EQ-5D index, the results of this study 
showed that patient with β-thalassemia (both groups) had 
many “problems” in different dimensions of the scale, ranging 
from 2.04% to 32.14%, and these problems have the highest 
rate in P/D and A/D dimensions. The results indicated that 
there was no significant difference between BMT and BTIC 
groups in SC, MO, and UA dimensions. However, significant 
Table 3. Results of EQ-5D Index and EQ VAS Scores
Indicator 
EQ-5D Index Score EQ VAS
Mean 95% CI P Mean 95% CI P
Gender         
Male 0.85 0.80 0.89 .221 70.86 67.09 74.62 .401
Female 0.88 0.85 0.92  73.23 69.21 77.25  
Age group         
<18 0.88 0.83 0.93 .584 72.97 68.38 77.57 .910
18-25 0.85 0.80 0.89  72.63 68.07 77.18  
≥25 0.85 0.80 0.91  69.46 64.39 74.54  
Years of school         
≤12 0.86 0.83 0.89  71.85 68.75 74.96  
>12 0.85 0.77 0.93 .740 71.85 66.04 77.66 .999
Income         
Low 0.88 0.83 0.92 .592 68.39 64.05 72.73 .042a
Middle 0.84 0.78 0.91  71.16 65.68 76.65  
High 0.85 0.81 0.90  76.61 72.30 80.92  
Urbanity         
Urban 0.85 0.82 0.89 .175 70.54 67.62 73.46 .006
Rural 0.92 0.84 1.00  82.81 76.06 89.56  
Supplementary insurance         
Yes 0.85 0.78 0.91 .638 71.79 66.92 76.66 .979a
No 0.86 0.83 0.90  71.87 68.58 75.17  
Treatment         
BTIC 0.87 0.84 0.90 .450 68.55 65.44 71.65 .000a
BMT 0.84 0.76 0.92  83.27 78.66 87.89  
Total 0.86 0.83 0.89  71.85 69.13 74.58  
Abbreviations: BTIC, blood transfusion plus iron chelation; BMT, bone marrow transplantation; VAS, visual analog scale.
a Statistically significant at P < .05; No signs: No significant. 
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Table 4. Results of Multiple Regression Analysis
Indicator 
EQ-5D Index Score EQ VAS Score
Coef SE P Coef SE P
Gender
Male Ref Ref
Female 0.05 0.03 .119 1.77 2.68 .509
Age group
<18 Ref Ref
18-25 -0.05 0.04 .197 -0.32 3.55 .928
≥25 -0.04 0.04 .292 -4.10 3.57 .251
Years of school
≤12 Ref Ref
>12 -0.01 0.04 .851 0.70 3.13 .824
Income
Low Ref Ref
Middle -0.03 0.04 .470 1.20 3.96 .762
High -0.02 0.05 .725 4.83 3.61 .182
Urbanity
Urban Ref Ref
Rural 0.07 0.04 .086 10.25 3.70 .006
Supplementary insurance 
Yes Ref Ref
No 0.00 0.04 .994 -0.19 3.13 .951
Treatment
BTIC Ref Ref
BMT -0.04 0.05 .498 11.88 3.31 .000
Abbreviations: BTIC, blood transfusion plus iron chelation; BMT, bone marrow transplantation; VAS, visual analog scale.
Notes: No signs: No significant. 
Table 5. Comparison of SF-36 Scores Between BMT and BTIC Patients
SF-36 
Subscales 
BTIC BMT
P 
Mean SD Mean SD
PF 84.93 17.60 93.07 10.90 .004a
RP 58.88 38.32 77.84 29.14 .003a
BP 81.68 20.09 81.36 20.82 .928
GH 64.24 21.82 68.41 20.22 .259
MH 65.66 19.78 70.55 15.48 .133
RE 55.92 40.35 78.79 39.43 .001a
SF 80.02 21.35 86.93 20.70 .058
VT 65.89 18.24 69.89 16.96 .195
PCS 48.23 7.09 51.65 6.60 .005a
MCS 45.19 9.76 49.53 9.59 .010
Abbreviations: RP, role limitations; PF, physical functioning; BP, bodily 
pain; GH, general health; VT, Vitality; RE, role limitations; MH, mental 
health; MCS, mental component scale; PCS, physical component scale; 
SF, social functioning; BTIC, blood transfusion plus iron chelation; BMT, 
bone marrow transplantation.
a Statistically significant at P < .05.
differences were observed in P/D and A/D dimensions. In 
terms of P/D, a higher percentage of BMT patients complained 
about blood transfusion methods (52.27% vs 26.32%), while a 
higher percentage of BTIC patients complained about A/D 
(34.87% to 6.82%).  Review of the literature showed that the 
most common complaints have been related to P/D and 
A/D.10,11 For instance, Shaligram et al10 and Mantovani et al11 
reported similar results in patients who received blood 
transfusion. However, the most common complaint reported 
in these studies was related to the P/D dimension (64% and 
60.5%, respectively), while in our study the most common 
complaint was related to the A/D dimension (34.87%). 
Problems related to A/D in cited studies were similar to our 
findings (33%, 39.5%, and 34.87%). In Shaligram et al,10 a 
higher percentage of patients had problems was much with 
the MO dimension that the patients studied in the present 
research (33% vs 3.95%). Therefore, these findings suggest 
that patients who receive blood transfusion have more A/D 
problems and require more attention. Regarding that 
estimation of EQ-5D score is only based on all dimension 
values, we were not able to do further analysis on the 
dimensions that are significantly different between 2 groups. 
The average EQ-5D index scores of BTIC and BMT patients 
were 0.87 and 0.84, respectively. The average EQ-5D index 
score of all the patients was 0.86, and there were no significant 
differences between these groups in EQ-5D index score. As 
EQ-5D includes only 5 dimensions of health it may not be the 
ideal and very sensitive measure to evaluate thalassemia 
patients health, but it is a general instrument to measure 
QALY by many organization like the National Institute for 
Health and Care Excellence (NICE). However, the average EQ 
VAS scores of BTIC and BMT patients were 68.55% and 
83.27%, respectively. This significant difference may be due to 
the fact that BMT patients do not experience the regular and 
long-term blood transfusion and iron chelation that BTIC 
patients undergo. Also the difference between EQ-5D and 
VAS could be explained partially by the dimensions of health 
which are not included in EQ-5D but will be considered 
subjectively by the patients in their evaluation using VAS. In a 
similar study by Mantovani et al,11 the average EQ VAS score 
of BTIC patients was 73, which could be due to timely and 
appropriate chelation therapy and access to treatment, 
support, and complete insurance coverage in that context 
(Italy). The present findings showed that 15.07%, 38.81%, and 
33.93% of the subjects in the age groups of <18, 18-25 and ≥25 
had A/D problems. Moreover, rural and urban patients were 
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significantly different in this dimension, indicating that age 
and residence have a significant effect on the HRQoL of 
patients with β-thalassemia. Also there were significant 
differences between patients with low-, middle-, and high-
income as well as patients in rural and urban areas in EQ VAS 
score. Multiple regression analysis for EQ-5D index showed 
that there was no significant correlation between demographic 
characteristics and therapeutic methods. Although EuroQol 
Group recommended to use UK value set in case, there is no 
local one but QoL is heavily depend on the socio-economic 
and cultural structure of each society and using value set from 
other countries may create biased result. However, there was a 
significant correlation between residence and therapeutic 
methods in EQ VAS. The average SF-36 scores of BTIC 
patients suggested that these patients had the highest physical 
function, which is similar to the results of similar studies 
conducted in Iran.8,16-20 Furthermore, in a study by Yengil et 
al,28 the BP dimension took the highest score after the SF 
dimension. Based on the results of this study, RE had the 
weakest function among other dimensions, which is consistent 
with other studies done in Iran.8,16 The mean of this dimension 
in Safizadeh et al19 was similar to our study, but RE was not 
the weakest dimension in their study. Contrary to these, the 
best function of RE were seen in Baraz Pordanjani’s study,17 
and Haghpanah et al18 showed that it has the greatest effect 
after physical functioning. The patients in our study had 
lower RE function compared to other dimensions. This is 
consistent with the results of Safizadeh et al19 and Khani et al.8 
Moreover, the mean of physical and mental dimensions in the 
present study were similar to those reported by Mantovani et 
al,11 but lower than those reported by Haghpanah et al.18 In 
addition, we found that the patients’ functionality in almost 
all the dimensions decreased with age. With increasing age as 
well as physical problems and functional limitation, patients 
encounter other problems such as extending family size, 
continuing education, and finding a good job, which will 
result in various psychological problems.16 Overall, comparing 
BTIC and BMT patients showed that regardless of physical 
pain which was similar in these groups, BMT patients had 
better functionality in all the other dimensions. The results 
also showed significant differences between the 2 groups in 
PF, RP, and RE, with higher scores in BMT patients. It seems 
that leaving regular blood transfusion that causes iron 
overloading and subsequent physical problems, not having to 
regularly visit medical centers, and not having to undergo 
blood transfusion and iron chelation therapy which may lead 
to absence from work or school and therefore loss of self-
confidence can positively affect patients’ morale and improve 
their mental health. Also as the data were collected during 
time BTIC patient refer for blood transfusion  while BMT 
group were collected 8 months to 18 years after BMT, different 
timing may also explain why BMT had higher QOL. Multiple 
linear regression analysis was used to eliminate the effect of 
confounding factors19 and showed that age, level of 
supplementary insurance, and therapeutic methods are 
associated with patients’ HRQoL. Although there might be 
other relevant variables such as diabetes mellitus (DM), 
hypogonadism, cardiomyopathy, graft-versus-host disease, 
etc. that may affect the QoL, but, patients medical records 
were incomplete and data about these factors were not valid 
to be included in the model. Safizadeh et al19 found gender 
differences in patients’ QoL, but unlike this study, found no 
Table 6. Multiple Linear Regression Model for SF-36 Scores
Variables PF RP BP GH MH RE SF VA PCS MCS
Gender
Male Ref
Female 1.14 1.97 0.17 1.63 2.17 5.82 -2.01 -0.91 -0.47 1.80
Age group
<18 Ref
18-25 9.23a 2.37 -2.15 3.78 -3.10 7.46 -0.39 -3.28 2.04 -2.57
≥25 4.73 9.60 -3.98 -2.66 -6.3b 8.64 -5.27 -5.12 1.27 -2.32
Years of school
≤12 Ref
>12 -2.91 -0.58 0.33 1.07 -4.57 8.89 -2.43 -2.82 -0.14 -1.02
Income
Low Ref
Middle -1.75 5.23 0.53 0.09 1.87 9.08 -0.88 -0.87 0.04 0.69
High -1.86 7.92 3.27 -2.32 -1.59 3.51 -3.66 -2.43 0.55 -0.68
Urbanity          
Urban Ref          
Rural 0.27 -3.06 4.72 6.10 5.41 -3.11 7.57 1.67 -0.32 2.04
Supplementary insurance          
Yes Ref          
No -0.57 -9.46 7.4b 3.11 -1.44 -4.5a -0.02 -1.30 1.82 -3.31a
Treatment          
BTIC Ref          
BMT 9.11a 16.85a -2.14a 4.27a 4.41a 22.45a 7.22 4.44 3.37a 4.11a
Abbreviations: RP, role limitations due to physical problems; PF, physical functioning; BP, bodily pain; GH, general health; VT, Vitality; RE, role limitations due 
to emotional problems; MH, mental health; MCS, mental component scale; PCS, physical component scale; SF, social functioning; BTIC, blood transfusion 
plus iron chelation; BMT, bone marrow transplantation.
a P < .05.
b P < .1.
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significant effect for age. However, a study conducted in 
Thailand showed that age was associated with HRQoL.7 
Moreover, Cheuk et al9 showed that BMT patients have higher 
QoL, especially in the physical dimension, which is consistent 
with the result of our study. Furthermore, Lawson et al29 
argued that BMT is the only way of treatment and achieving 
QoL in major thalassemia patients. Consistent with previous 
studies, our findings showed that BTIC patients have lower 
physical problems than mental problems,11 and BMT patients 
have higher scores in physical and psychosocial domains.9 
However, more studies need to be done with a cost-
effectiveness approach to help policy makers in BTIC or BMT 
development across the country.
Conclusion
It seems that BMT provides higher HRQoL in patients with 
β-Thalassemia, both in physical and mental aspects. Using 
analysis of multiple regression test, we found no significant 
correlation between EQ-5D index scores, demographic 
parameters, and treatment methods. However, residence 
(urban or rural) and type of treatment were significantly 
associated with health (HRQoL, EQ VAS). Furthermore, 
SF-36 scores showed significant differences between BTIC 
and BMT patients in RP, RE, PF, and PCS. Since patients’ 
age is combined in the analysis, such approach may have 
limitations such as heterogeneity in the QoL assessments; 
and ratings from young children may not be combinable with 
ratings for older children and adults. Also since this study is 
the first research on QoL of BMT β-thalassemia patients in 
Iran, further investigation is needed to confirm the results of 
our study, which proposes BMT as the preferred method for 
treating patients with β-thalassemia.
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